Last reviewed · How we verify
NCT05883709
A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL
trial testing Tafasitamab Injection in Diffuse Large B-cell Lymphoma in 15 participants. Status unknown.
30 December 2023
Quick facts
| Lead sponsor | Zhao Weili |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 15 |
| Start date | 1 July 2023 |
| Primary completion | 30 December 2023 |
| Estimated completion | 30 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Tafasitamab Injection — full drug profile →
Conditions studied
- Diffuse Large B-cell Lymphoma — all drugs for Diffuse Large B-cell Lymphoma →
Sponsor
Zhao Weili — full company profile →
Who can join
18 and older, any sex, with Diffuse Large B-cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the real-world efficacy of Tafasitamab combined with Lenalidomide base regimen in patients with relapsed or refractory DLBCL, with objective response rate as the primary end point.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Epigenetic Symphony in Diffuse Large B-Cell Lymphoma: Orchestrating the Tumor Microenvironment.
Caloian AD, Cristian M, Calin E, Pricop AR, et al · · 2025 · cited 7× · PMID 40299416 · DOI 10.3390/biomedicines13040853
Verify or expand the search:
- PubMed search for NCT05883709
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diffuse Large B-cell Lymphoma
Currently open trials in the same condition.
- NCT06977711 — Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large · Phase 1 · recruiting
- NCT06846463 — Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+ · Phase 2 · recruiting
- NCT06870487 — A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers · Phase 1 · active not recruiting
- NCT06651853 — Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL · Phase 2 · recruiting
- NCT06503263 — Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL · Phase 2 · recruiting
Other Zhao Weili trials
Trials by the same sponsor.
- NCT05979792 — Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Periphe · EARLY_PHASE1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05883709 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhao Weili
- Last refreshed: 1 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05883709.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing